Phibro Animal Health Files 8-K on Officer Compensation, Leadership Changes

TL;DR

**Phibro Animal Health just filed an 8-K hinting at executive compensation and leadership changes.**

AI Summary

Phibro Animal Health Corporation filed an 8-K on February 6, 2024, to report a "Regulation FD Disclosure" and information regarding "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers." This filing indicates potential changes in executive compensation or leadership, which could impact the company's strategic direction and financial performance. Investors should monitor subsequent filings for details on these compensatory arrangements and any new appointments, as they could signal shifts in management's priorities or a response to recent performance.

Why It Matters

This filing signals potential changes in executive compensation or leadership at Phibro Animal Health, which could influence future company strategy and financial health. Investors need to watch for specifics on these changes to understand their impact.

Risk Assessment

Risk Level: medium — The filing indicates potential changes in executive compensation and leadership without providing specifics, creating uncertainty about future management and financial commitments.

Analyst Insight

A smart investor would monitor Phibro Animal Health's subsequent filings for specific details on the compensatory arrangements and any new officer appointments, as these will provide clarity on the company's future leadership and financial commitments.

Key Numbers

• $0.0001 — Par value per share (Par value of Phibro Animal Health Corporation's Class A Common Stock)

Key Players & Entities

• Phibro Animal Health Corporation (company) — the registrant filing the 8-K
• NASDAQ Stock Market (company) — the exchange where PAHC Class A Common Stock is registered
• February 6, 2024 (date) — date of earliest event reported and filing date
• $0.0001 (dollar_amount) — par value per share of Class A Common Stock

Forward-Looking Statements

• Phibro Animal Health Corporation will provide more detailed information on executive compensation changes in a subsequent filing. (Phibro Animal Health Corporation) — high confidence, target: 2024-05-06
• The 'Regulation FD Disclosure' mentioned in the filing will relate to an upcoming earnings call or investor presentation. (Phibro Animal Health Corporation) — medium confidence, target: 2024-03-06

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share PAHC NASDAQ Sto
• $650,000 — d will receive an annual base salary of $650,000 and an annual bonus opportunity with a
• $135,000 — d will receive a signing bonus equal to $135,000 (the "Signing Bonus"), which will be pa
• $20 — ng five years from the Grant Date, from $20 to $60 and above, subject to Mr. David'
• $60 — years from the Grant Date, from $20 to $60 and above, subject to Mr. David's conti

Filing Documents

• tm245238d2_8k.htm (8-K) — 33KB
• tm245238d2_ex99-1.htm (EX-99.1) — 6KB
• tm245238d2_ex99-1img01.jpg (GRAPHIC) — 5KB
• 0001104659-24-010954.txt ( ) — 221KB
• pahc-20240206.xsd (EX-101.SCH) — 3KB
• pahc-20240206_lab.xml (EX-101.LAB) — 33KB
• pahc-20240206_pre.xml (EX-101.PRE) — 22KB
• tm245238d2_8k_htm.xml (XML) — 4KB

02

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On February 6, 2024, Phibro Animal Health Corporation ("Phibro" or the "Company") announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024 (the "Start Date"), pursuant to the terms and conditions of that certain offer letter, entered into between Phibro and Mr. David dated October 12, 2023 (the "Offer Letter"). Mr. Richard Johnson, who has served as Phibro's interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David. Mr. David, age 52, brings over 30 years of experience in commercial and financial leadership roles. Mr. David's most recent role was Executive Vice President and Group President, US Operations, Diagnostics, Biodevices and Insurance at Zoetis Inc. Prior to that, he served as Executive Vice President and Group President, International Operations, Aquaculture, Biodevices and Insurance at Zoetis. Mr. David was the Chief Financial Officer at Zoetis from 2016-2021, where he maintained a well-capitalized and financially disciplined business, creating significant value for shareholders and earlier in his career, he served as Senior Vice President of Finance Operations for Zoetis during its Initial Public Offering in 2013. Before the Zoetis IPO, Mr. David served in various financial roles at Pfizer Inc., including Vice President of Global Finance for Pfizer Animal Health and Vice President of Finance for the U.S. Primary Care franchise. Mr. David has a Bachelor of Science in Finance from Binghamton University and a Masters of Business Administration in Finance from New York University. There are no family relationships between Mr. David and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Addit

01

ITEM 7.01 REGULATION FD DISCLOSURE. On February 6, 2024, the Company issued a press release announcing Mr. David joining the Company and his appointment as Chief Financial Officer effective as of the Start Date. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 and in the press release is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

FINANCIAL STATEMENTS AND EXHIBITS

FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated February 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PHIBRO ANIMAL HEALTH CORPORATION Registrant Date: February 6, 2024 By: /s/ Judith Weinstein Name: Judith Weinstein Title: Senior Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR